Overview
Biopharmaceutical company reported Q4 PEMGARDA net product revenue up 25% yr/yr
Loss per share for 2025 beat analyst expectations
Net loss for 2025 beat analyst estimates
Outlook
Invivyd expects top-line data from DECLARATION trial mid-2026
Company anticipates advancing RSV candidate VBY329 toward IND readiness in 2H 2026
Invivyd's cash reserves are expected to support DECLARATION trial and pipeline programs
Result Drivers
PEMGARDA REVENUE GROWTH - Q4 PEMGARDA revenue increased 25% yr/yr and 31% qtr/qtr, driven by commercial execution and appeal for monoclonal antibody prophylaxis
OPERATING EXPENSES REDUCED - Operating expenses were reduced by nearly half, demonstrating financial discipline
Company press release: ID:nGNX8b1R3F
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Revenue | $53.43 mln | ||
FY EPS | Beat | -$0.30 | -$0.39 (4 Analysts) |
FY Net Income | Beat | -$52.49 mln | -$57.82 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Invivyd Inc is $10.00, about 484.8% above its March 4 closing price of $1.71
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)